Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic adipose-derived mesenchymal stem cells + fibrin glue
- Development stage
- Unknown
- Lead developer
- Seoul National University Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intratendinous
01
Overview
This investigational cell-based therapy consists of allogeneic adipose-derived mesenchymal stem cells (Allo-ASC) suspended in a fibrin glue carrier. Developed by researchers at Seoul National University Hospital, it is specifically designed for the treatment of lateral epicondylitis (tennis elbow). The therapy is administered via intratendinous injection into common extensor tendon defects under ultrasound guidance. The stem cells are intended to promote tissue regeneration and repair of the damaged tendon through paracrine signaling and differentiation, while the fibrin glue acts as a biological scaffold to localize and maintain the cells at the site of injury. Clinical studies, including a Phase II randomized controlled trial, have evaluated its safety and efficacy in improving elbow pain, performance scores, and structural tendon defects.
- Other names
- Allo-ASC mixed with fibrin glueallogeneic adipose-derived mesenchymal stem cells in fibrin gluefibrin glue-Seoul National University Hospital-lateral epicondylitis
Beyond the preview
Go deeper on allogeneic adipose-derived mesenchymal stem cells + fibrin glue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic adipose-derived mesenchymal stem cells + fibrin glue.